Highlights,Institutional investors such as Rhumbline Advisers adjusted their stake, reducing shares in the last ...

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Germans Trias i Pujol Research Institute (IGTP ...

The "Make America Healthy Again" commission is reviewing certain vaccines as some states push to restrict the use of COVID-19 ...

US scientists have discovered an alarming syndrome linked to the most commonly used Covid jab in the UK as the number of ...

Additional presentations from Seer and collaborators will highlight the Proteograph Product Suite’s role in deep proteomic studies to understand tissue biology, uncover biomarkers for cardiometabolic ...

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Germans Trias i Pujol Research Institute (IGTP ...

Penn researchers are developing new treatments using mRNA technology to combat a range of diseases, namely celiac disease ...

CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its ...

Five years after the start of the COVID-19 pandemic, public weariness and irresponsible politics are hampering an effective ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Moderna ( NASDAQ: MRNA) Q4 2024 Earnings Conference Call February 14, 2025 8:00 AM ET Lavina Talukdar - Senior Vice President, Investor Relations Stephane Bancel - Chief Executive Officer Jamey Mock - ...

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.